8.2.4 Other immunomodulating drugs

Homepage

Search the NeLM

Medicines A-Z

Find key information about medicines by name (prototype)

Browse by Categories:

Browse by NeLM area:

BNF Category

470 library items in 8.2.4 Other immunomodulating drugs

Filter results by:

Date Published

NeLM Area

News
Other Library Updates
Health In Focus
Evidence
Medicines A-Z
Communities
Formularies

Results filtered by:

Category

8: Malignant disease and immunosuppression (remove) , 8.2 Drugs affecting the immune response (remove) , 8.2.4 Other immunomodulating drugs (remove)

Sort by: Display summary:

Results 1 - 10 of 470

Result page:
Previous
|
1
2
3
4
5
6
7
8
9
10
11
|
Next

1.

Updated national IV monograph on Natalizumab

Source: Medusa,
Date published: 16/05/2012

Category:

8.2.4 Other immunomodulating drugs | Drug Administration

NeLM Area:

News

Link- registration required
2.

FDA Drug Safety Communication: Revised recommendations for cardiac monitoring and use of fingolimod (Gilenya®)

Source: FDA,
Date published: 15/05/2012

Category:

8.2.4 Other immunomodulating drugs | Adverse Drug Reactions | Food &Drug Administration (FDA) | Multiple sclerosis

NeLM Area:

News

Link
3.

Horizon scanning: US and EU regulatory authorities accept for review marketing applications for oral dimethyl fumarate (BG-12) for treatment of multiple sclerosis

Source: PharmaLive,
Date published: 10/05/2012

Category:

8.2.4 Other immunomodulating drugs | Food &Drug Administration (FDA) | Multiple sclerosis | New drugs

NeLM Area:

News

Link
4.

RCTs of continuous lenalidomide treatment for multiple myeloma

Source: New England Journal of Medicine (NEJM),
Date published: 10/05/2012

Category:

8.2.4 Other immunomodulating drugs | Multiple myeloma | Transplantation

NeLM Area:

News

Abstract (newly diagnosed)

Abstract (stem cell transplantation 1)

Abstract (stem cell transplantation 2)

Editorial- full text may be restricted to subscribers
5.

FDA Drug Safety Communication: Increased risk of second primary malignancies in patients taking lenalidomide for multiple myeloma

Source: FDA MedWatch,
Date published: 08/05/2012

Category:

8.2.4 Other immunomodulating drugs | Adverse Drug Reactions | Food &Drug Administration (FDA) | Multiple myeloma

NeLM Area:

News

Link
6.

Thalidomide for managing cancer cachexia

Source: Cochrane Library,
Date published: 27/04/2012

Category:

8.2.4 Other immunomodulating drugs | Drug reviews | Oncology

NeLM Area:

Evidence > Drug Specific Reviews

Link to Abstract
7.

Additional data from phase III CARE-MS II trial of alemtuzumab (LemtradaTM) for multiple sclerosis

Source: BioSpace ,
Date published: 26/04/2012

Category:

8.2.4 Other immunomodulating drugs | Multiple sclerosis | New drugs

NeLM Area:

News

Link to BioSpace report

NeLM report CARE-MS II trial
8.

Costing template for NICE guidance on fingolimod for highly active relapsing–remitting multiple sclerosis

Source: NICE,
Date published: 25/04/2012

Category:

8.2.4 Other immunomodulating drugs | Clinical guidelines | Multiple sclerosis | National Institute of Clinical Excellence (NICE)

NeLM Area:

News

Link to costing template

Link to guidance (TA 254)
9.

NICE issues final guidance recommending fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis

Source: NICE,
Date published: 25/04/2012

Category:

8.2.4 Other immunomodulating drugs | Clinical guidelines | Multiple sclerosis | National Institute of Clinical Excellence (NICE)

NeLM Area:

Evidence > Guidelines

Link to guidance (TA 254)
10.

European Medicines Agency provides new advice to better manage risk of adverse effects on the heart with fingolimod (Gilenya®)

Source: EMA,
Date published: 20/04/2012

Category:

8.2.4 Other immunomodulating drugs | Adverse Drug Reactions | European Agency for the Evaluation of Medicinal Products (EMEA) | Multiple sclerosis

NeLM Area:

News

Press release

Q&A document

Previous NeLM story on EMA review

US FDA recommendations

Results 1 - 10 of 470

Result page:
Previous
|
1
2
3
4
5
6
7
8
9
10
11
|
Next